Adaptive Biotechnologies
ADPT
226 hedge funds and large institutions have $931M invested in Adaptive Biotechnologies in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 81 increasing their positions, 60 reducing their positions, and 25 closing their positions.
135% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $522K
76% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 25
35% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 60
8% more funds holding
Funds holding: 209 → 226 (+17)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.7% less ownership
Funds ownership: 94.37% → 91.67% (-2.7%)
14% less capital invested
Capital invested by funds: $1.08B → $931M (-$152M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.3M |
| 2 |
Goldman Sachs
New York
|
+$5.33M |
| 3 |
AAP
Aristotle Atlantic Partners
Sarasota,
Florida
|
+$5.32M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$5.31M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$96.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$2.78M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$2.44M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.4M |
ADPT Hedge Fund Activity: Q3 2022 in Review
226 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2022, worth a combined $931M — down 14% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ADPT positions and 25 closed out — a net gain of 19 holders — while 81 added to existing stakes and 60 trimmed.
The largest buyer was BlackRock, adding an estimated $10.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $96.9M.
- 226 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2022, up from 209 in Q2 2022.
- Funds reported $931M of Adaptive Biotechnologies stock for Q3 2022, down 14% quarter-over-quarter.
- 44 funds opened new Adaptive Biotechnologies positions in Q3 2022 and 25 closed out, a net change of +19 holders.
- The largest Adaptive Biotechnologies buyer in Q3 2022 was BlackRock, an estimated $10.3M added.
- The largest Adaptive Biotechnologies seller in Q3 2022 was T. Rowe Price Associates, an estimated $96.9M sold.
Based on aggregated 13F filings for Q3 2022.